Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested

Fineline Cube Apr 24, 2026
Company Drug

Aosaikang Pharmaceutical Receives NMPA Review for ASKC200 Liniment from Propella Therapeutics

Fineline Cube Apr 14, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the National Medical Products Administration...

Company R&D

HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency

Fineline Cube Apr 14, 2023

HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the...

Company Deals

Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion

Fineline Cube Apr 14, 2023

PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed...

Company

Huadong Medicine Reports 9.12% YOY Revenue Growth and 13.24% Increase in Net Profits for 2022

Fineline Cube Apr 14, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has released its 2022...

Company

BeiGene Launches LATAM Expansion with New Office in São Paulo, Brazil

Fineline Cube Apr 14, 2023

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced its first...

Company R&D

Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment

Fineline Cube Apr 13, 2023

US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its...

Company Drug

Convalife Pharmaceuticals’ Mefuparib Earns Orphan Drug Designation for Cholangiocarcinoma

Fineline Cube Apr 13, 2023

Shanghai-based Convalife Pharmaceuticals has announced that it has received orphan drug designation (ODD) status from...

Company Deals

VintaBio Secures $64M Funding to Revolutionize Viral Vectors for Cell and Gene Therapy

Fineline Cube Apr 13, 2023

New biotech VintaBio, founded in Philadelphia, Pennsylvania (United States), announces the appointment of CEO David...

Company Deals

Alebund Pharmaceuticals Secures $29M in Pre-Series C Funding and $116M Loan for R&D and Manufacturing

Fineline Cube Apr 13, 2023

Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB...

Company Drug

Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R/R DLBCL

Fineline Cube Apr 13, 2023

Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China’s Overland Pharmaceuticals and Swiss...

Company Drug

Novartis’ Jakavi Secures NMPA Approval for Acute GVHD Treatment in China

Fineline Cube Apr 13, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received a new indication...

Company Drug

Chengdu Hyperway Pharmaceuticals’ HBW-004285 Gets NMPA Tacit Approval for Pain Treatment

Fineline Cube Apr 13, 2023

China-based Chengdu Hyperway Pharmaceuticals has announced receiving tacit clinical trial approval from the National Medical...

Company Medical Device

Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study

Fineline Cube Apr 12, 2023

Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that its Iberis multi-electrode renal...

Company Drug

Grand Pharmaceutical’s APP13007 Achieves Clinical Endpoints in US Trials for Post-Operative Treatment

Fineline Cube Apr 12, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that a Phase II clinical study...

Company Drug

Sirnaomics Commences Phase I Clinical Trial for Factor Xl RNAi Drug STP122G

Fineline Cube Apr 12, 2023

Sirnaomics Ltd (HKG: 2257) has announced the commencement of a single-center, randomized, double-blind, placebo-controlled, sequence...

Company Drug

Shanghai Fosun Pharmaceutical Submits Market Approval Filing for Daxibotulinumtoxin A in China

Fineline Cube Apr 12, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a market approval filing to...

Company Drug

Junshi Biosciences’ Senaparib Meets Primary Endpoint in Phase III Ovarian Cancer Study

Fineline Cube Apr 12, 2023

China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has declared that the Phase III FLAMES study...

Company

Porton Pharma Solutions Expands with Biomacromolecules R&D and Manufacturing Center in Shanghai

Fineline Cube Apr 12, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has initiated the construction of...

Company Deals

Blueray Med Secures Tens of Millions in Series A+ Financing for Advanced Laser Medicine Devices

Fineline Cube Apr 12, 2023

Blueray Med, a leading high-end laser medicine device manufacturer based in Xi’an, has reportedly secured...

Company Deals

Specialised Therapeutics to Commercialize Akeso’s PD-1 Inhibitor Penpulimab in APAC

Fineline Cube Apr 12, 2023

Singapore-based Specialised Therapeutics Asia Pte Ltd (ST) has been appointed to handle the commercialization of...

Posts pagination

1 … 528 529 530 … 656

Recent updates

  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
  • Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction
  • Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market
  • China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Company Medical Device

Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction

Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.